Simple decision-making between a Vitamin K antagonist and a non-Vitamin K antagonist oral anticoagulant: Using the SAMe-TT2R2 score

European Heart Journal - Cardiovascular Pharmacotherapy

Volumn 1, Issue 3, 2015, Pages 150-152

  Proietti, Marco ^a,b   Lip, Gregory Y H ^a,c  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c AALBORG UNIVERSITY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; NON VKA ORAL ANTICOAGULANT; UNCLASSIFIED DRUG; WARFARIN;

ATRIAL FIBRILLATION; BLEEDING; CARDIOVASCULAR DISEASE ASSESSMENT; CEREBROVASCULAR ACCIDENT; CLINICAL DECISION MAKING; HUMAN; INTERNATIONAL NORMALIZED RATIO; MORTALITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SAME TT2R2 SCORE; THROMBOEMBOLISM; THROMBOSIS PREVENTION;

EID: 85019302310     PISSN: 20556837     EISSN: 20556845     Source Type: Journal    
DOI: 10.1093/ehjcvp/pvv012     Document Type: Review

References (16)

1. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, Hindricks G, Kirchhof P; ESC Committee for Practice Guidelines (CPG). 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012; 33:2719-2747.
2. De Caterina R, Husted S, Wallentin L, Andreotti F, Arnesen H, Bachmann F, Baigent C, Huber K, Jespersen J, Kristensen SD, Lip GY, Morais J, Rasmussen LH, Siegbahn A, Verheugt FW,Weitz JI. Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease. Thromb Haemost 2013;110:1087-1107.
3. Gallego P, Roldan V, Marín F, Romera M, Valdés M, Vicente V, Lip GY. Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation. Thromb Haemost 2013;110:1189-1198.
4. Husted S, de Caterina R, Andreotti F, Arnesen H, Bachmann F, Huber K, Jespersen J, Kristensen SD, Lip GY, Morais J, Rasmussen LH, Siegbahn A, Storey RF,Weitz JI; ESC Working Group on Thrombosis Task Force on Anticoagulants in Heart Disease. Non-vitamin K antagonist oral anticoagulants (NOACs): no longer new or novel. Thromb Haemost 2014;111:781-782.
5. Azoulay L, Dell'Aniello S, Simon TA, Renoux C, Suissa S. Initiation of warfarin in patients with atrial fibrillation: early effects on ischaemic strokes. Eur Heart J 2014; 35:1881-1887.
6. Tung JM, Mamdani MM, Juurlink DN, Paterson JM, Kapral MK, Gomes T. Rates of ischemic stroke during warfarin treatment for atrial fibrillation. Stroke 2015; doi: 10.1161/STROKEAHA.114.007852.
7. Apostolakis S, Sullivan RM, Olshansky B, Lip GY. Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT2R2 score. Chest 2013;144:1555-1563.
8. Clarkesmith DE, Pattison HM, Lip GY, Lane DA. Educational intervention improves anticoagulation control in atrial fibrillation patients: the TREAT randomised trial. PLoS ONE 2013;8:e74037.
9. Poli D, Antonucci E, Testa S, Lip GY. A prospective validation of the SAME-TT2R2 score: how to identify atrial fibrillation patients who will have good anticoagulation control on warfarin. Intern Emerg Med 2014;9:443-447.
10. Gallego P, Roldán V, Marin F, Gálvez J, Valdés M, Vicente V, Lip GY. SAMe-TT2R2 score, time in therapeutic range, and outcomes in anticoagulated patients with atrial fibrillation. Am J Med 2014;127:1083-1088.
11. Abumuaileq RR, Abu-Assi E, Raposeiras-Roubin S, López-López A, Redondo-Diéguez A, Á lvarez-Iglesias D, Rodríguez-Mañero M, Peña-Gil C, González-Juanatey JR. Evaluation of SAMe-TT2R2 risk score for predicting the quality of anticoagulation control in a real-world cohort of patients with non-valvular atrial fibrillation onvitamin-K antagonists. Europace 2015; pii:euu353 [Epub ahead of print].
12. Lip GY, Haguenoer K, Saint-Etienne C, Fauchier L. Relationship of the SAMe-TT2R2 score to poor-quality anticoagulation, stroke, clinically relevant bleeding, and mortality in patients with atrial fibrillation. Chest 2014;146:719-726.
13. Skov J, Bladbjerg EM, Bor MV, Gram J. SAMeTT2R2 does not predict time in therapeutic range of the international normalized ratio in patients attending a high-quality anticoagulation clinic. Chest 2014;145:187-188.
14. Chan NC, Paikin JS, Hirsh J, Lauw MN, Eikelboom JW, Ginsberg JS. New oral anticoagulants for stroke prevention in atrial fibrillation: impact of study design, double counting and unexpected findings on interpretation of study results and conclusions. Thromb Haemost 2014;111:798-807.
15. Schulman S. New oral anticoagulant agents-general features and outcomes in subsets of patients. Thromb Haemost 2014;111:575-582.
16. National Clinical Guideline Centre (UK). Atrial Fibrillation: The Management of Atrial Fibrillation. London: National Institute for Health and Care Excellence (UK), 2014.